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The urokinase plasminogen activator (u-PA) is intimately associated with tumour invasion and metastases. Surgery facilitates
accelerated metastatic tumour growth in murine models, a phenomenon related to elevated perioperative bacterial lipopolysaccaride
(LPS) and inflammatory cytokine levels. The objectives of the study were to examine the role of u-PA in cytokine-enhanced tumour
cell invasion in vitro and surgery-induced accelerated metastatic tumour growth in vivo and to assess the potential benefit of a novel
selective u-PA inhibitor WXC-340 in this setting. CT-26 murine colorectal carcinoma cells were stimulated with LPS, tumour necrosis
factor a (TNF-a) and interleukin 6 (IL-6). Cell supernatant u-PA expression and activity were determined using a colorimetric assay
and Western blot analysis, respectively. Baseline and cytokine-stimulated in vitro invasion were assessed using ECmatrix invasion
chambers. Two established murine models of accelerated metastatic tumour growth were used to investigate the consequences of
u-PA inhibition on postoperative metastatic tumour burden. The effect of u-PA inhibition in vitro and in vivo was examined using the
novel selective u-PA inhibitor, WXC-340. Proinflammatory cytokine stimulation significantly enhanced in vitro u-PA expression,
activity and extracellular matrix invasion by approximately 50% compared to controls (Po0.05). This was abrogated by WXC-340. In
vivo WXC-340 almost completely ameliorated both LPS- and surgery-induced, metastatic tumour growth compared to controls
(P40.05). In conclusion, u-PA cascade is actively involved in cytokine-mediated enhanced tumour cell invasion and LPS and surgery-
induced metastatic tumour growth. Perioperative u-PA inhibition with WXC-340 may represent a novel therapeutic paradigm.
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Surgery remains the only definitive curative modality for colorectal
cancer (Meyerhardt and Mayer, 2005). Unfortunately, mounting
clinical and experimental evidence suggests that the perioperative
milieu may facilitate the progression of occult metastatic disease
(DaCosta et al, 1998; Mitsudomi et al, 1999; Demicheli et al, 2001).
Multiple factors have been implicated in this phenomenon
including perioperative immune suppression and elimination of
putative tumour-suppressing agents with primary tumour excision
(Li et al, 2001). Surgery produces elevated levels of proinflamma-
tory cytokines such as tumour necrosis factor a (TNF-a) and
interleukin 6 (IL-6), consummate with procedure magnitude
(Shiromizu et al, 2000). Such proinflammatory cytokines are
increasingly implicated in the development and progression of
primary and metastatic neoplastic disease (Coussens and Werb,
2002). Furthermore in vitro and in vivo studies have incriminated
perioperative exposure to systemic bacterial endotoxin or lipo-
polysaccaride (LPS), the primary glycolipid component in the cell
wall of Gram-negative organisms, in surgery-induced accelerated
metastatic tumour growth, suggesting both a direct cellular role
and indirect cytokine-mediated effect. In a murine colorectal
carcinoma (CT-26) model of surgery-induced accelerated meta-
static tumour growth, laparotomy was associated with a significant
elevation in postoperative inflammatory cytokine levels specifically
TNF-a and IL-6, compared to subjects undergoing laparoscopy
or receiving anaesthesia alone (Shiromizu et al, 2000). Using the
same cell line, Luo et al (2004) demonstrated that LPS-mediated
enhanced metastatic lung tumour growth was TNF-a dependent. In
addition, by targeting the effectors mechanisms activated by these
proinflammatory cytokines such as the anti-apoptotic cycloox-
yenase 2 (COX-2) pathway, it may be possible to modify this
accelerated postoperative metastatic tumour growth rate (Qadri
et al, 2005).
Extracellular matrix invasion is a fundamental pre-requisite for
tumour metastases. To facilitate this, cancer cells sabotage native
protease systems (Egeblad and Werb, 2002). Indeed, many of the
tumour-promoting effects of the aforementioned inflammatory
cytokines are secondary to upregulation of proinvasive com-
pounds such as matrix metalloproteases and beta integrins (Wang
et al, 2003). The urokinase plasminogen activator system
comprising urokinase plasminogen activator (u-PA), its receptor
urokinase plasminogen activator receptor (u-PAR) (CD87) and
two endogenous inhibitors, plasminogen activator inhibitor 1 and Revised 3 November 2006; accepted 22 November 2006
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s2 (PAI-1, PAI-2) is another such proteolytic system actively
subverted by the neoplastic process (Sidenius and Blasi, 2003).
Urokinase plasminogen activator catalyses the generation of
plasmin from its precursor plasminogen, which in turn promotes
the degradation of extracellular matrix components. Binding of
u-PA to its receptor facilitates direct plasmin-mediated proteolysis
and indirect activation of additional protease systems such as
matrix metalloproteases thereby serving to increase the tissue-
remodelling ability and invasion capacity of carcinoma cells
(Sidenius and Blasi, 2003). Reflecting its clinical relevance, elevated
serum and tumour levels of u-PA, u-PAR and PAI-1 are poor
prognostic indicators in a variety of neoplasms including colo-
rectal, breast, lung and renal carcinoma (Duffy, 2002). Moreover,
proinflammatory cytokines increase the concentration and activity
of u-PA produced by human colorectal cancer cells in vitro at
concentrations similar to postoperative serum levels (Tran-Thang
et al, 1996).
Thus, the u-PA system is an attractive therapeutic target.
Mimetics of the growth factor-like domain of u-PA inhibit
experimental and spontaneous metastases in a murine model of
lung cancer (Kobayashi et al, 1996) and u-PAR antagonists inhibit
primary tumour growth and angiogenesis in syngenic mouse
models (Min et al, 1996). A recently developed selective u-PA
inhibitor, WX-UK1 impaired development of lung metastases in a
rat model of spontaneous metastatic orthotopic breast adenocar-
cinoma, whereas Ertongur et al (2004) demonstrated that this
compound inhibited in vitro tumour cell Matrigel invasion by a
variety of human cancer cell lines (Setyono-Han et al, 2005). WXC-
340 is a novel, related second-generation synthetic, low molecular
weight protease inhibitor that selectively inhibits activated u-PA in
a dose-dependent manner.
Given the prominence of the u-PA system in promoting tumour
cell invasion and the upregulation of components of the u-PA
system by elevated inflammatory cytokines at concentrations
similar to levels seen post laparotomy, inhibition of the u-PA
protease system may represent an innovative and potent
perioperative therapeutic strategy to attenuate surgery-induced
accelerated tumour growth. The aims of this study therefore, were
to determine if proinflammatory cytokines at levels similar to
those seen postoperatively upregulated u-PA expression and to
establish if this increase enhanced u-PA-mediated invasion
in vitro. We additionally investigated the role of the u-PA system
in LPS and surgery-induced accelerated metastatic tumour growth
in vivo and also ascertained if the novel synthetic u-PA inhibitor,
WXC-340 ameliorated in vitro cytokine-enhanced tumour cell
invasion and in vivo surgery and LPS-induced accelerated
metastatic tumour growth.
METHODS
Cell culture
The murine CT-26 colorectal carcinoma cell line was grown in
RPMI 1640 medium containing 10% fetal calf serum, 100
unitsml
 1 penicillin, streptomycin sulphate (100mgml
 1) and
2.0mmoll
 1 glutamine. Cells were maintained at 371Ci na
humidified 5% CO2 atmosphere and subcultured by trypsinisation
with 0.05% trypsin–0.02% ethylenediaminetetraacetic acid
(EDTA) when confluence approached (all from Life Technologies,
Paisley, Scotland).
Cell stimulation and sample preparation
Cells cultured in six-well plates (Falcon; 1 10
6cellswell
 1) were
exposed to various concentrations of LPS (Escherichia coli O55B5)
(100, 1000 and 10000ngml
 1), TNF-a (1, 2.5 and 5ngml
 1) and
IL-6 (1, 2.5 and 5ngml
 1) for different time periods (0, 6, 12, 18
and 24h) at 371C in a humidified 5% CO2 environment (all Sigma-
Aldrich, St Louis, MO, USA). Conditioned medium was removed,
centrifuged at 5000r.p.m. for 5min and frozen at  801Co r
analysed immediately. Urokinase plasminogen activator blockade
involved preincubation with 0.3mgml
 1 WXC-340 (optimal
inhibitory concentration was determined from dose–response
curves) for 1h. WXC-340 was kindly provided by Dr Bernd
Muehlenweg (Wilex AG, Munich, Germany). Urokinase plasmino-
gen activator activity was also impaired by incubating-cells with
37.5mgml
 1 of a u-PA function-blocking antibody (American
Diagnostica, Greenwich, London).
For Western blot analysis of activated u-PA in conditioned
culture medium, medium was concentrated 40-fold using centricon
10 ultrafiltration tubes (Millipore, Ireland).
UPA activity assay
Active murine u-PA levels were quantified by use of a u-PA activity
assay kit (Innovative Research, Michigan, USA), in accordance
with the manufacturer’s instructions.
The u-PA inhibitor WXC-340
WXC-340 is a synthetic low molecular weight, serine protease, u-
PA inhibitor. For this study u-PA activity was initially assessed
after incubation with various concentrations of WXC-340 from
0.01 to 1mgml
 1 WXC 340 as shown in Table 1. At 0.3mgml
 1
WXC-340, there was little change in u-PA activity. At concentra-
tions above 1mgml
 1, WXC-340 there was decreased cell viability
as assessed by MTT assay. Hence for the stimulation experiments
and chemoinvasion assay 0.3mgml
 1 WXC-340 was used.
Western blot analysis
Equal amounts of protein were resolved on SDS–PAGE, transfer to
nitrocellulose membrane, and incubated with specific anti-u-PA
and anti-u-PAR antibodies (Santa Cruz, CA, USA) for 18h at
41C. After washing and incubating with secondary antibodies,
immunoreactive proteins were visualised by the ECL detection
system (Amersham Biosciences Piscataway, NJ, USA).
Tumour invasion assay
In vitro tumour cell invasion was assessed using the extracellular
matrix (ECmatrix) invasion chamber (Chemicon, Temecula, CA,
USA). This consists of a invasion chamber with cell culture inserts
containing an 8-mm pore size positron emission tomography
membrane lined by a thin layer of ECmatrix (ExtraCellualr matrix,
a reconstituted basement membrane matrix of proteins derived
from the Engelbreth Holm-Swarm (EHS) mouse tumour), which
sits in a 96-well plate that acts as a reservoir for chemoattractant.
Briefly, 0.5ml serum-free medium containing 1 10
5cellsml
 1
was added to the cell culture insert of the invasion chamber. This
was supplemented with TNF-a, Il-6 (2.5ngml
 1) or serum free
medium. FBS (20mgml
 1) was added in the outer chamber as a
Table 1 u-PA activity after incubation with various concentrations of WXC-340
WXC-340mg/ml 0.00 0.01 0.05 0.075 0.10 0.20 0.30 0.40 0.50 0.75 1.00 1.50
u-PA activity 0.80
(70.05)
0.78
(70.061)
0.61
(70.037)
0.43
(70.052)
0.31
(70.072)
0.23
(70.046)
0.2
(70.067)
0.18
(70.064)
0.16
(70.051)
0.2
(70.081)
0.16
(70.09)
0.15
(70.087)
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schemoattractant. WXC-340 was added to the upper chamber to
assess the effect of u-PA inhibition on in vitro invasion. The cells
were then incubated at 371C in humidified 5% CO2 conditions for
18h. Medium in the upper chamber was discarded and the
chamber washed. Invaded cells attached to the bottom of the
matrix membrane were detached and lysed in cell lysate buffer.
Cell lysate was then stained with CyQuant GR Dye (Chemicon,
Temecula, CA, USA). Fluorescence was measured using a
fluorescence plate reader at an excitation wavelength of 485nm
and an emission wavelength of 520nm. A standard curve to
convert measured fluorescence to cell number was constructed
utilising known cell numbers. Values are expressed as the number
of invaded cells per 1 10
6.
Animals
Six- to eight-week-old female Balb/c mice were used in all
experiments. Mice were housed in barrier cages under controlled
environmental conditions (12/12h of light/dark cycle, 5575%
humidity, 231C) and had free access to standard laboratory chow
and water. All animal procedures were conducted in the University
Biological Services Unit under a license from the Department of
Health and Children (Republic of Ireland). Age- and weight-
matched mice were used throughout.
Perioperative proinflammatory cytokine levels
Mice were separated into three groups receiving anaesthesia
alone, anaesthesia and intraperitoneal (i.p.) LPS, and anaesthesia
and laparotomy, respectively. Three mice per group were killed at
each time point 0, 3, 6 and 12h after surgery (Shiromizu et al,
2000) and blood samples were obtained by cardiac puncture.
Following centrifugation, serum levels of IL-6 and TNF-a were
determined by ELISA in accordance with the manufacturer’s
instructions.
Experimental CT-26 lung metastatic model and
interventions
Subconfluent tumour cells were harvested and passed through a
40mm cell strainer, washed twice in PBS and resuspended in PBS at
2 10
5ml
 1. Single-cell suspensions of greater than 90% viability
based on Trypan Blue exclusion were used. Mice were injected with
10
5 CT 26 cells via the tail vein. Nine days later, mice were
randomised to one of five experimental groups (n¼50, 10 per
group). All animals were anaesthetised with halothane. Group 1
received PBS (1ml) and group 2, 10mg LPS (in 1ml PBS) via i.p.
injection as reported by Luo et al (2004). Group 3 underwent
laparotomy as described previously by Condon et al (2004). This
group underwent a midline xiphoid to pubis incision, which
exposed the peritoneal contents for 15min before closure (5min)
with a continuous 3/0 nylon suture (Ethicon, Somerville, NJ, USA).
These control groups received subcutaneous PBS daily post
intervention. Group 4 received subcutaneous WXC-340 1h before
LPS administration, whereas group 5 received subcutaneous WXC-
340 1h before laparotomy. Both these groups received daily
subcutaneous WXC-340 thereafter. After 7 days, mice were killed
and weighed (Figure 1). The lungs were resected, weighed and lung
tumour nodules were counted. Specimens were paraffin-embedded
following fixation with 4% formaldehyde in phosphate-buffered
saline. Tissue sections, 7mm thick, were stained with haematoxylin
and eosin.
To examine u-PA expression following LPS administration or
surgery, mice (n¼3 per group) were killed 24h postintervention.
Tumour nodules were microdissected and underwent sonication.
Urokinase plasminogen activator activity was assessed as de-
scribed previously. Microdissected tumour cell homogenates were
generated by lysis in ice-cold lysis buffer (50mM Tris–HCl, pH 7.5,
150mM NaCl, 1% nonident P-40, 1mM EDTA, 1mM NaF, 1mM
sodium orthovanadate with freshly added 1mM phenylmethylsul-
phonyl fluoride, 0.5mM DTT, 0.5mM PMSF and protease inhibitor
cocktail (Roche, Mannheim, Germany)), clarified by centrifugation
105 CT-26
Tail vein injection
30, 6-week-old female BALB/C
Control (n =10)
Anaesthesia + PBS
LPS (n =10)
Anaesthesia + 10  g LPS
intraperitoneal injection
Laparotomy (n =10)
Anaesthesia + midline
abdominal incision and
two layered closure
LPS + u-PA inhibitor
0.3 mg/kg wxc-340 s.c.
1 h pre-op
Laparotomy + u-PA inhibitor
0.3 mg/kg s.c.
1 h pre-op
Daily u-PA inhibitor
0.3 mg/kg wxc-340 s.c.
Sacrifice
Lung tumour nodules
Lung weight
Lung/body weight ratio
Sacrifice
Lung tumour nodules
Lung weight
Lung/body weight ratio
Sacrifice
Lung tumour nodules
Lung weight
Lung/body weight ratio
Sacrifice
Lung tumour nodules
Lung weight
Lung/body weight ratio
Sacrifice
Lung tumour nodules
Lung weight
Lung/body weight ratio
Daily PBS s.c. Daily PBS s.c. Daily PBS s.c.
Daily u-PA inhibitor
0.3 mg/kg wxc-340 s.c.
Figure 1 Schematic diagram outlining experimental procedure: 9 days after tail vein injection, animals were anaesthesied and randomised to one of five
groups. Group 1 received an i.p. injection of PBS (1ml), group 2 10mg LPS (in 1ml PBS), group 3 underwent laparotomy as described previously, group 4
received 0.3mgkg
 1 WXC-340 (in 1ml PBS) 1h before intraperitoneal injection of 10mgml
 1 LPS and group 5 received 0.3mgKg
 1 WXC-340 (in 1ml
PBS) 1h before laparotomy. Subsequently groups 1–3 received subcutaneous PBS (1ml) daily, whereas groups 4 and 5 received subcutaneous 0.3mgkg
 1
WXC-340 ( in 1ml PBS).
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sat 7500g and protein concentrations were determined
using a Micro BCA protein assay reagent kit (Pierce, Rockford,
IL, USA).
Statistical analysis
Results are presented as the mean7s.d. Statistical analysis was
performed using analysis of variance (ANOVA). Statistical
significance was accepted at a P-value less than 0.05.
RESULTS
Stimulation of CT-26 cancer cells with TNF-a and IL-6
leads to enhanced u-PA activity in stimulated cell
supernatants that are abrogated by the u-PA inhibitor
WXC-340
The urokinase plasminogen activator activity in CT-26 cell
supernatant was increased with proinflammatory cytokine (TNF-
a and IL-6) but not LPS stimulation in a time and dose-dependent
manner (Figure 2). Following dose optimisation experiments, both
base line and stimulated u-PA activity were abrogated almost
completely by pre treatment of cells with WXC-340 at concentra-
tions of 0.3mgml
 1 (P¼0.039 compared to control groups).
Lipopolysaccaride stimulation had no direct effect on u-PA activity
in CT-26 cell supernatant.
Stimulation of CT-26 cancer cells with TNF-a and IL-6
leads to enhanced u-PA expression in stimulated cell
supernatants
Mirroring this increased u-PA activity, u-PA expression in
concentrated CT-26 supernatant as demonstrated by Western blot
analysis was enhanced by stimulation with the proinflammatory
cytokines TNF-a and IL-6 (Figure 3).
The u-PA inhibitor WXC-340 ameliorates baseline and
cytokine stimulated in vitro invasion by CT-26 cells
TNF-a and IL-6 accentuated in vitro ECmatrix invasion (Figure 4).
Baseline CT-26 matrix invasion was significantly inhibited by
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Figure 2 Inflammatory cytokines enhance u-PA activity in a time (A) and dose (B)-dependent manner. Pretreatment with WXC-340 impaired baseline
and cytokine-enhanced u-PA activity. Results are expressed as the mean7s.d. and are representative of four separate experiments, conducted in triplicate.
Statistical significance was compared with control cells incubated with culture medium alone (*Po0.05).
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Figure 3 Western blot analysis of concentrated conditioned medium
demonstrating increased activated u-PA with cytokine stimulation. (lane
1:control, lane 2: 10000ngml
 1 LPS, lane 3: 2.5ngml
 1 TNF-a, lane 4:
2.5ngml
 1 IL-6).
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sincubation with WXC-340 (P¼0.045 compared to control groups).
Pre-treatment of CT-26 cells with 0.3mgml
 1 WXC-340 before
cytokine stimulation ameliorated cytokine-induced increases in
CT-26 invasion in vitro (P¼0.027 compared to control groups)
(Figure 4).
Intraperitoneal LPS and surgery increase proinflammatory
cytokine levels
Serum IL-6 and TNF-a levels were significantly elevated after
laparotomy and ip LPS administration when compared to control
groups (Figure 5).
Intraperitoneal LPS and surgery increase metastatic
tumour burden, u-PA expression and activity in
microdissected lung metastatic tumour nodules
As reported previously both LPS and a standardised laparotomy
significantly increased the total metastatic nodule numbers, lung
weight and lung weight- to- body ratio compared to animals
receiving i.p. PBS (P¼0.01) (Condon et al, 2004). Microdissected
tumour nodule lysates from animals in the LPS and surgery groups
(n¼3) demonstrated enhanced u-PA expression on Western blot
analysis and u-PA activity on colormetric assay compared to
control animals (P¼0.031) (Figure 6a and b, respectively).
Abrogation of LPS and surgery stimulated enhanced
metastatic tumour burden by the u-PA inhibitor WXC-340
Animals treated with 0.3mgkg
 1, WXC-340 (before i.p. LPS or
standardised laparotomy, in conjunction with subsequent daily
subcutaneous injection) developed fewer lung tumour nodules
(Figure 7a), had lower lung weights (Figure 7b) and lung to body
weight ratios (Figure 7c) compared to age- and gender- matched
controls (Po0.019, compared to PBS controls).
Toxicity profile
Serine protease inhibitors are important components in the
coagulation cascade (Setyono-Han et al, 2005). There was no
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Figure 4 Cytokine stimulation with TNF-a and IL-6 (2.5ngml
 1)
significantly enhances CT-26 in vitro ECmatrix invasion. This cytokine-
mediated increased invasion is inhibited by the novel u-PA inhibitor
WXC-340 at a concentration of 0.3mgml
 1. Results are expressed as
the mean7s.d. and are representative of four separate experiments,
conducted in triplicate. Statistical significance was compared with control
cells incubated with culture medium alone (*Po0.05) or cytokine
stimulated cells (**Po0.05).
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Figure 6 Western blot analysis of microdissected tumour nodules
revealed accentuated activated u-PA expression in animals, which had
received LPS and undergone surgery compared to control mice (A). There
was increased u-PA activity in microdissected tumour nodule lysates from
in animals which had received LPS and undergone surgery compared to
control mice (*Po0.05) (B). n¼3 mice per group.
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sevidence of haemorrhagic complications and the coagulation
parameters of treated mice were not disturbed. Furthermore, in
animals that received WXC-340, all wounds remained intact with
no evidence of breakdown. Repeated WXC-340 treatment of mice
was well tolerated with no signs of overt toxicity. WXC-340 did not
result in changes in body weight or other organs. There was no
evidence of skin irritation at the injection site.
DISCUSSION
Increasing evidence suggests that surgery may accelerate the
growth of minimal residual disease. Multiple factors have been
implicated in this phenomenon, the plethora of proinflammatory
cytokines, specifically TNF-a and IL-6, released by the surgical
insult, probably play a pre-eminent role (Shiromizu et al, 2000;
Luo et al, 2004). Identification of downstream effector mechanisms
utilised by tumour cells to enhance invasion in this setting could
highlight novel targets for possible use in this perioperative period
of therapeutic opportunity (Qadri et al, 2005).
One such effector mechanism subverted by the neoplastic
process is the urokinase plasminogen activator system, which
directly and indirectly promotes tumour cell invasion and
metastasis through multiple mechanisms including plasmin-
mediated pericellular proteolysis, enhanced vitronectin adhesion
and activation of pro-metastatic intracellular pathways such as src
and ERF 1 and 2 (Ahmed et al, 2003; Sidenius and Blasi, 2003).
Furthermore u-PA is potently upregulated by the proinflammatory
cytokines TNF-a and IL-6 in a variety of human cancer cell lines
in vitro and the u-PA system is significantly activated by infection
and sepsis in vivo as evidenced by increased circulating levels of
u-PA (Robbie et al, 2000; Abraham et al, 2003).
We demonstrate that TNF-a and Il-6, the primary inflammatory
cytokines elevated by i.p. LPS injection or standardised laparo-
tomy, enhance u-PA secretion and activity by CT-26 murine
colorectal carcinoma in vitro. This cytokine-mediated enhanced
u-PA production is parlayed into increased in vitro ECmatrix
invasion. The novel u-PA inhibitor WXC-340 inhibits both basal
and cytokine augmented in vitro invasion, indicative of the
prominent role of u-PA in cytokine-enhanced in vitro invasion.
Using two well-defined models of accelerated metastatic tumor
growth, we confirmed that both LPS and standardised laparotomy
significantly accentuated metastatic tumour burden. Western blot
analysis of micro-dissected metastatic tumor nodules revealed
increased u-PA expression in the LPS and surgery groups
compared to controls (n¼3). Furthermore, treatment with
subcutaneous WXC-340 ameliorated both the LPS and surgery-
induced increases in metastatic tumour load. Collectively these
results support a role for u-PA in postoperative tumour growth
and may represent a novel therapeutic target in the perioperative
setting.
Proinflammatory cytokines, elevated postoperatively, have an
emerging role in surgery-induced accelerated growth of metastatic
lesions. Although not the primary focus of this study, the findings
are in agreement with Luo et al (2004) and support the rationale of
anti-cytokine interventions in the postoperative phase. WXC-340
is a potent inhibitor of u-PA leading to impairment of the
urokinase plasminogen activator cascade and ultimately reduced
cancer cell invasion and metastases. Our results suggest that
decreased u-PA-dependent proteolysis is the primary pathway
involved; however, additional u-PA-mediated mechanisms such as
angiogenesis and cell signalling may also be beneficially altered.
Urokinase plasminogen activator is a contributor to the coagula-
tion cascade. In our study, there was no evidence of any
haemorrhagic complications or derangement of coagulation
parameters. Furthermore, there was no skin irritation at the
injection site unlike reports involving other u-PA inhibitors
(Kobayashi et al, 1996).
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Figure 7 Treatment of animals with WXC-340 abrogated LPS and
surgery associated accelerated metastatic tumour growth (*Po0.05). Mice
that received WXC-340 before LPS administration and subsequently daily
subcutaneous WXC-340 (0.3mgkg
 1) had significantly lower numbers of
tumour nodules (A), lung weight (B) and lung-to-body weight ratio (C)
than control animals receiving daily PBS (
@; Po0.05). Gross specimens (D)
and H and E staining (E) demonstrating significantly lower numbers of
tumour nodules in the WXC-340-treated mice.
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sOther components of the u-PA system, namely u-PAR and PAI-
1, promote tumour progression (Duffy, 2002; Sidenius and Blasi,
2003). Expression of u-PAR and PAI-1 by stromal and cellular
tumour components are substantially increased by proinflamma-
tory cytokines in vitro and sepsis significantly increases serum
PAI-1 levels (Robbie et al, 2000; Abraham et al, 2003). Thus,
although this study focused on u-PA and its inhibition, other
elements of this cascade are also possibly involved and warrant
further investigation. Development of selective synthetic inhibitors
of the aforementioned molecules and deployment in the perio-
perative period signifies an original therapeutic modality.
In conclusion, proinflammatory cytokines increase u-PA
expression and activity in vitro resulting in enhanced u-PA-
mediated extracellular matrix invasion, which is partially amelio-
rated by u-PA inhibition using the novel agent WXC-340. In two
models of surgery-induced accelerated metastatic tumour growth,
WXC-340 significantly reduced metastatic burden suggesting that
the u-PA cascade is a valid target in the perioperative period.
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